Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

Yusuf Yazici,1 Lin Xie,2 Adesuwa Ogbomo,2 Lorie A Ellis,3 Kavitha Goyal,4 Amanda Teeple,5 Ismail Simsek6 1Rheumatology, New York University, School of Medicine, New York, NY, USA; 2Health Economics and Outcomes Research, STATinMED Research, Ann Arbor, MI, USA; 3Real World Value and Evidence, Janssen...

Full description

Saved in:
Bibliographic Details
Main Authors: Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Simsek I
Format: article
Language:EN
Published: Dove Medical Press 2018
Subjects:
rheumatoid arthritis
biosimilar
CT-P13
continuer
treatment patterns
Medicine (General)
R5-920
Online Access:https://doaj.org/article/e53d3e9542784a82828170823409189e
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/e53d3e9542784a82828170823409189e

Similar Items